Evaluating dose response from flexible dose clinical trials

Lipkovich, Ilya; Adams, David H.; Mallinckrodt, Craig; Faries, Doug; Baron, David; Houston, John P
January 2008
BMC Psychiatry;2008, Vol. 8, Special section p1
Academic Journal
Background: The true dose effect in flexible-dose clinical trials may be obscured and even reversed because dose and outcome are related. Methods: To evaluate dose effect in response on primary efficacy scales from 2 randomized, double-blind, flexible-dose trials of patients with bipolar mania who received olanzapine (N = 234, 5-20 mg/day), or patients with schizophrenia who received olanzapine (N = 172, 10-20 mg/day), we used marginal structural models, inverse probability of treatment weighting (MSM, IPTW) methodology. Dose profiles for mean changes from baseline were evaluated using weighted MSM with a repeated measures model. To adjust for selection bias due to non-random dose assignment and dropouts, patient-specific time-dependent weights were determined as products of (i) stable weights based on inverse probability of receiving the sequence of dose assignments that was actually received by a patient up to given time multiplied by (ii) stable weights based on inverse probability of patient remaining on treatment by that time. Results were compared with those by unweighted analyses. Results: While the observed difference in efficacy scores for dose groups for the unweighted analysis strongly favored lower doses, the weighted analyses showed no strong dose effects and, in some cases, reversed the apparent "negative dose effect." Conclusion: While naïve comparison of groups by last or modal dose in a flexible-dose trial may result in severely biased efficacy analyses, the MSM with IPTW estimators approach may be a valuable method of removing these biases and evaluating potential dose effect, which may prove useful for planning confirmatory trials.


Related Articles

  • Improved Treatment of AL Amyloidosis.  // Annals of Internal Medicine;1/20/2004, Vol. 140 Issue 2, pI27 

    Reports on an activity program to improve treatment of Al Amyloidosis. Production of too much light amyloids by abnormal plasma cells; Deposition of this protein in different organs leading to diseases; Lengthening of survival by a drug called melphalan; Collection of a special type of cells...

  • Retrospective analysis of factors associated with quetiapine dosage in the acute and subsequent six-month maintenance treatment of bipolar disorders. Ling Zhang; Gang Wang; Jiong Luo; Qing-E Zhang; Qian Zhao; Qi-Ying Deng; Xin Ma // Neuropsychiatric Disease & Treatment;2013, Vol. 9, p575 

    Background: Although quetiapine has often been used as monotherapy or adjunctive therapy in bipolar disorder, there is very limited clinical evidence regarding prescribing practices for quetiapine as maintenance treatment for bipolar disorder. Methods: We reviewed the inpatient and outpatient...

  • Dose-Ranging in Clinical Trials: Rationale and Proposed Use with Placebo or Positive Controls. Freston, James W. // American Journal of Gastroenterology;May1986, Vol. 81 Issue 5, p307 

    Presents an overview of the position paper of the American College of Gastroenterology on issues related to dose-ranging clinical trials. Definition of the therapeutic index; Collection of dose-response information; Ethical issues on the practice of using placebo controls.

  • Treating Clotting Disorders: A Balance between Preventing Clots and Bleeding.  // Women's Health Advisor;Feb2013, Vol. 17 Issue 2, p3 

    The article focuses on positive and negative effect of anticoagulant drugs on human body. It informs about a study on warfarin, an anticoagulant drug that shows bleeding rates from the drug are higher than in clinical trials, and often are fatal depending on the amount of dose of drug that a...

  • Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. Reardon, David; Vredenburgh, James; Desjardins, Annick; Peters, Katherine; Sathornsumetee, Sith; Threatt, Stevie; Sampson, John; Herndon, James; Coan, April; McSherry, Frances; Rich, Jeremy; McLendon, Roger; Zhang, Steven; Friedman, Henry // Journal of Neuro-Oncology;Jul2012, Vol. 108 Issue 3, p499 

    To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of dasatinib, an inhibitor of the Src family kinase proteins, with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, among recurrent malignant glioma patients. Once daily dasatinib was...

  • Single nucleotide polymorphism and its dynamics for pharmacogenomics. Katara, Pramod // Interdisciplinary Sciences: Computational Life Sciences;Jun2014, Vol. 6 Issue 2, p85 

    Pharmacogenomics is the study of how the genetic makeup determines the response to a therapeutic intervention. It has the capability to revolutionize the practice of medicine by personalized approach for treatment through the use of novel diagnostic tools. Pharmacogenomic based approaches reduce...

  • New Glatiramer Acetate Dosing Regimen for MS May Be Safer. Worcester, Sharon // Neurology Reviews;Nov2014, Vol. 22 Issue 11, p54 

    The article focuses on a research conducted by Jerry S. Wolinsky, Director of the MS Research Group at the University of Texas Health Science Center in Houston, Texas, on glatiramer acetate dosing regimen for multiple sclerosis (MS). It reports on the Glatiramer Acetate Low Frequency Safety &...

  • Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Lee, J.-M.; Sarosy, G. A.; Annunziata, C. M.; Azad, N.; Minasian, L.; Kotz, H.; Squires, J.; Houston, N.; Kohn, E. C. // British Journal of Cancer;2/10/2010, Vol. 102 Issue 3, p495 

    Background: We previously reported preliminary results of our phase I study of continuous daily sorafenib with bevacizumab every other week for solid tumours. Toxicity was moderate, leading to additional dose levels (DL) testing intermittent sorafenib dosing.Methods:...

  • American College of Rheumatology.  // BioWorld Today;10/21/2009, Vol. 20 Issue 203, p3 

    The article reports that Celgene Corp. of Summit, New Jersey, has shown from its data of Phase II psoriatic arthritis trial of apremilast that it has improved its treatment performance within three months. The study found that 40 percent of twice-daily and 39.1 percent of once-daily patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics